NCT06401343View on ClinicalTrials.gov

Use of SGLT2i in noHCM With HFpEF

PHASE4RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2025

Conditions
Hypertrophic CardiomyopathyHeart Failure With Preserved Ejection Fraction
Interventions
DRUG

Empagliflozin 10 MG

Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.

Trial Locations (1)

100037

RECRUITING

Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV